Pharsight

1. Drug name - ABILIFY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759350	OTSUKA	Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders	Mar, 2027 (4 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Adjunctive treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

2. Drug name - ABILIFY MYCITE KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759350	OTSUKA	Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders	Mar, 2027 (4 years from now)
US9444503	OTSUKA	Active signal processing personal health signal receivers	Nov, 2027 (5 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Adjunctive treatment of major depressive disorder (mdd); Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

3. Drug name - ABRAXANE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8034375 (Pediatric)	ABRAXIS BIOSCIENCE	Combinations and modes of administration of therapeutic agents and combination therapy	Feb, 2027 (4 years from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription

4. Drug name - ACTOPLUS MET

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101660	TAKEDA PHARMS USA	Solid preparation	Jan, 2027 (4 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
500MG;EQ 15MG BASE	TABLET;ORAL	Prescription
850MG;EQ 15MG BASE	TABLET;ORAL	Prescription

5. Drug name - ACULAR LS

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008338	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8008338 (Pediatric)	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Nov, 2027 (5 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.4%	SOLUTION/DROPS;OPHTHALMIC	Prescription

6. Drug name - ADRENACLICK

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7905352	IMPAX	Kits containing medicine injection devices and containers	Apr, 2027 (4 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
EQ 0.15MG/DELIVERY	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued
EQ 0.3MG/DELIVERY	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

7. Drug name - ADVIL ALLERGY SINUS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863287	GLAXOSMITHKLINE	Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines	Feb, 2027 (4 years from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG;200MG;30MG	TABLET;ORAL	Over the counter

8. Drug name - ALSUMA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7811254	MERIDIAN MEDCL	Autoinjector with needle depth adapter	Aug, 2027 (4 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes

Dosage: INJECTABLE;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE;SUBCUTANEOUS	Discontinued

9. Drug name - ALTABAX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7875630	ALMIRALL	Process salts compositions and use	Feb, 2027 (4 years from now)

Drugs and Companies using RETAPAMULIN ingredient

Treatment: NA

Dosage: OINTMENT;TOPICAL

Strength	Dosage	Availability
1%	OINTMENT;TOPICAL	Prescription

10. Drug name - AMITIZA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338639	SUCAMPO PHARMA LLC	Soft-gelatin capsule formulation	Jan, 2027 (4 years from now)
US8779187	SUCAMPO PHARMA LLC	Soft-gelatin capsule formulation	Jan, 2027 (4 years from now)
US8026393	SUCAMPO PHARMA LLC	Soft-gelatin capsule formulation	Oct, 2027 (5 years from now)

Drugs and Companies using LUBIPROSTONE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
8MCG	CAPSULE;ORAL	Prescription
24MCG	CAPSULE;ORAL	Prescription

11. Drug name - AMYVID

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8506929	AVID RADIOPHARMS INC	Styrylpyridine derivatives and their use for binding and imaging amyloid plaques	Apr, 2027 (4 years from now)
US7687052	AVID RADIOPHARMS INC	Styrylpyridine derivatives and their use for binding and imaging amyloid plaques	Apr, 2027 (4 years from now)
CN101522624B	AVID RADIOPHARMS INC	Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques	Mar, 2027 (4 years from now)
CN101522624A	AVID RADIOPHARMS INC	Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques	Mar, 2027 (4 years from now)
IN288160B	AVID RADIOPHARMS INC	Styrylpyridine Compounds	Mar, 2027 (4 years from now)
IN200807219P1	AVID RADIOPHARMS INC	Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques	Mar, 2027 (4 years from now)
EP2363392A1	AVID RADIOPHARMS INC	Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques	Mar, 2027 (4 years from now)
EP2363392B1	AVID RADIOPHARMS INC	Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques	Mar, 2027 (4 years from now)

Drugs and Companies using FLORBETAPIR F-18 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
10ML (13.5-51mCi/ML)	SOLUTION;INTRAVENOUS	Discontinued
10-30ML (13.5-51mCi/ML)	SOLUTION;INTRAVENOUS	Prescription
10-50ML (13.5-51mCi/ML)	SOLUTION;INTRAVENOUS	Prescription

12. Drug name - ANORO ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7488827	GLAXOSMITHKLINE	Muscarinic acetylcholine receptor antagonists	Dec, 2027 (5 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511304	GLAXOSMITHKLINE	Medicament dispenser	Jun, 2027 (4 years from now)
US9333310	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2027 (4 years from now)
US8113199	GLAXOSMITHKLINE	Counter for use with a medicament dispenser	Oct, 2027 (5 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription

13. Drug name - ANTIZOL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553863	PAR PHARM INC	Ultrapure 4-methylpyrazole	Jun, 2027 (4 years from now)

Drugs and Companies using FOMEPIZOLE ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
1.5GM/1.5ML (1GM/ML)	INJECTABLE;INJECTION	Discontinued

14. Drug name - ARGATROBAN IN SODIUM CHLORIDE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7687516	EAGLE PHARMS	Alcohol free formulation of argatroban	Sep, 2027 (4 years from now)
US7589106	EAGLE PHARMS	Alcohol free formulation of argatroban	Sep, 2027 (4 years from now)

Drugs and Companies using ARGATROBAN ingredient

Treatment: Method of treating an argatroban treatable condition; Method of treating thrombosis

Dosage: INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
50MG/50ML (1MG/ML)	INJECTABLE;INTRAVENOUS	Discontinued

15. Drug name - ARNUITY ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2027 (4 years from now)
US8113199	GLAXOSMITHKLINE	Counter for use with a medicament dispenser	Oct, 2027 (5 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.05MG/INH	POWDER;INHALATION	Prescription
0.1MG/INH	POWDER;INHALATION	Prescription
0.2MG/INH	POWDER;INHALATION	Prescription

16. Drug name - AUBAGIO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6794410 (Pediatric)	SANOFI AVENTIS US	Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis	Mar, 2027 (4 years from now)

Drugs and Companies using TERIFLUNOMIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
7MG	TABLET;ORAL	Prescription
14MG	TABLET;ORAL	Prescription

17. Drug name - AUVI-Q

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108	KALEO INC	Medicament delivery device having an electronic circuit system	Feb, 2027 (4 years from now)
US8206360	KALEO INC	Devices, systems and methods for medicament delivery	Feb, 2027 (4 years from now)
US9724471	KALEO INC	Devices, systems, and methods for medicament delivery	May, 2027 (4 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
EQ 0.1MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription
EQ 0.15MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription
EQ 0.3MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription

18. Drug name - AVEED

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640	ENDO PHARMS INC	Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels	Mar, 2027 (4 years from now)
US8338395	ENDO PHARMS INC	Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels	May, 2027 (4 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired); hypogonadotropic hypogonadism (congenital or acquired).

Dosage: INJECTABLE;INTRAMUSCULAR

Strength	Dosage	Availability
750MG/3ML (250MG/ML)	INJECTABLE;INTRAMUSCULAR	Prescription

19. Drug name - AXIRON

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9289586	ELI LILLY AND CO	Spreading implement	Feb, 2027 (4 years from now)
US8419307	ELI LILLY AND CO	Spreading implement	Feb, 2027 (4 years from now)
US8807861	ELI LILLY AND CO	Spreading implement	Feb, 2027 (4 years from now)
US8435944	ELI LILLY AND CO	Method and composition for transdermal drug delivery	Sep, 2027 (4 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of increasing the testosterone blood level of a person in need thereof; A method of transdermal administration of a physiologically active agent to a subject.

Dosage: SOLUTION, METERED;TRANSDERMAL

Strength	Dosage	Availability
30MG/1.5ML ACTUATION	SOLUTION, METERED;TRANSDERMAL	Discontinued

20. Drug name - AZILECT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7815942	TEVA	Rasagiline formulations of improved content uniformity	Aug, 2027 (4 years from now)

Drugs and Companies using RASAGILINE MESYLATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.5MG BASE	TABLET;ORAL	Prescription
EQ 1MG BASE	TABLET;ORAL	Prescription

21. Drug name - BALCOLTRA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7838042	AVION PHARMS	Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions	Jun, 2027 (4 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.02MG;0.1MG	TABLET;ORAL	Prescription

22. Drug name - BAXDELA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7728143	MELINTA	Salt and crystalline forms thereof of a drug	Nov, 2027 (5 years from now)

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 300MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

23. Drug name - BELBUCA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9655843	BDSI	Transmucosal delivery devices with enhanced uptake	Jul, 2027 (4 years from now)
US8147866	BDSI	Transmucosal delivery devices with enhanced uptake	Jul, 2027 (4 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Treatement of pain by transmucosal delivery of buprenorphine

Dosage: FILM;BUCCAL

Strength	Dosage	Availability
EQ 0.075MG BASE	FILM;BUCCAL	Prescription
EQ 0.15MG BASE	FILM;BUCCAL	Prescription
EQ 0.3MG BASE	FILM;BUCCAL	Prescription
EQ 0.45MG BASE	FILM;BUCCAL	Prescription
EQ 0.6MG BASE	FILM;BUCCAL	Prescription
EQ 0.75MG BASE	FILM;BUCCAL	Prescription
EQ 0.9MG BASE	FILM;BUCCAL	Prescription

24. Drug name - BELEODAQ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835501	ACROTECH	Pharmaceutical formulations of HDAC inhibitors	Oct, 2027 (5 years from now)

Drugs and Companies using BELINOSTAT ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
500MG/VIAL	POWDER;INTRAVENOUS	Prescription

25. Drug name - BREO ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511304	GLAXO GRP LTD	Medicament dispenser	Jun, 2027 (4 years from now)
US9333310	GLAXO GRP LTD	Medicament dispenser	Oct, 2027 (4 years from now)
US8113199	GLAXO GRP LTD	Counter for use with a medicament dispenser	Oct, 2027 (5 years from now)

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.1MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription
0.2MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription

26. Drug name - BUNAVAIL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9655843	BDSI	Transmucosal delivery devices with enhanced uptake	Jul, 2027 (4 years from now)
US8147866	BDSI	Transmucosal delivery devices with enhanced uptake	Jul, 2027 (4 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Treatment: Treatment of opioid dependence; Maintenance treatment of opioid dependence

Dosage: FILM;BUCCAL

Strength	Dosage	Availability
EQ 2.1MG BASE;EQ 0.3MG BASE	FILM;BUCCAL	Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE	FILM;BUCCAL	Discontinued
EQ 6.3MG BASE;EQ 1MG BASE	FILM;BUCCAL	Discontinued

27. Drug name - BYDUREON

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884092 (Pediatric)	ASTRAZENECA AB	Methods for treating diabetes and reducing body weight	Feb, 2027 (4 years from now)
US8329648 (Pediatric)	ASTRAZENECA AB	Methods for treating diabetes and reducing body weight	Feb, 2027 (4 years from now)
US8906851 (Pediatric)	ASTRAZENECA AB	Method for treating diabetes	Feb, 2027 (4 years from now)
US8501698	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Jun, 2027 (4 years from now)
US8758292	ASTRAZENECA AB	Administering apparatus with functional drive element	Nov, 2027 (5 years from now)
US8501698 (Pediatric)	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2027 (5 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued
2MG	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued

28. Drug name - BYDUREON BCISE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8329648 (Pediatric)	ASTRAZENECA AB	Methods for treating diabetes and reducing body weight	Feb, 2027 (4 years from now)
US9884092 (Pediatric)	ASTRAZENECA AB	Methods for treating diabetes and reducing body weight	Feb, 2027 (4 years from now)
US8906851 (Pediatric)	ASTRAZENECA AB	Method for treating diabetes	Feb, 2027 (4 years from now)
US8501698	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Jun, 2027 (4 years from now)
US8501698 (Pediatric)	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2027 (5 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/0.85ML (2MG/0.85ML)	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription

29. Drug name - BYFAVO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9777007	ACACIA	Short-acting benzodiazepine salts and their polymorphic forms	Jul, 2027 (4 years from now)
US9914738	ACACIA	Short-acting benzodiazepine salts and their polymorphic forms	Jul, 2027 (4 years from now)
US10472365	ACACIA	Short-acting benzodiazepine salts and their polymorphic forms	Jul, 2027 (4 years from now)

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 20MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

30. Drug name - BYVALSON

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7838552	ALLERGAN	Compositions comprising nebivolol	Oct, 2027 (5 years from now)

Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient

Treatment: Method of treating hypertension

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 5MG BASE;80MG	TABLET;ORAL	Discontinued

31. Drug name - CAMCEVI KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572857	ACCORD	Pharmaceutical compositions with enhanced stability	Jan, 2027 (4 years from now)
US10646572	ACCORD	Pharmaceutical compositions with enhanced stability	Jan, 2027 (4 years from now)
US9744207	ACCORD	Pharmaceutical compositions with enhanced stability	Jan, 2027 (4 years from now)

Drugs and Companies using LEUPROLIDE MESYLATE ingredient

Treatment: NA

Dosage: EMULSION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 42MG BASE	EMULSION;SUBCUTANEOUS	Prescription

32. Drug name - CARDENE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455524	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (4 years from now)
US10758616	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (4 years from now)
US7659291	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (4 years from now)
US9364564	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (5 years from now)
US7612102	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (5 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
25MG/10ML (2.5MG/ML)	INJECTABLE;INJECTION	Discontinued
40MG/200ML (0.2MG/ML)	INJECTABLE;INTRAVENOUS	Discontinued
20MG/200ML (0.1MG/ML)	INJECTABLE;INTRAVENOUS	Prescription

33. Drug name - CHLORAPREP ONE-STEP

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7422388	BECTON DICKINSON CO	Applicator for coloring antiseptic	Apr, 2027 (4 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SPONGE;TOPICAL

Strength	Dosage	Availability
2%;70% (3ML)	SPONGE;TOPICAL	Over the counter
2%;70% (10.5ML)	SPONGE;TOPICAL	Over the counter
2%;70% (26ML)	SPONGE;TOPICAL	Over the counter
2%;70% (1ML)	SPONGE;TOPICAL	Over the counter
2%;70% (1.5ML)	SPONGE;TOPICAL	Over the counter

34. Drug name - CHLORHEXIDINE GLUCONATE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7935093	SAGE PRODS	Disinfectant delivery system and method of providing alcohol-free disinfection	Oct, 2027 (4 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Treatment: For the preparation of skin prior to surgery; helps reduce bacteria that can potentially cause skin infection

Dosage: CLOTH;TOPICAL

Strength	Dosage	Availability
2%	CLOTH;TOPICAL	Over the counter

35. Drug name - COLAZAL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7452872 (Pediatric)	VALEANT PHARMS INTL	Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives	Feb, 2027 (4 years from now)
US7625884 (Pediatric)	VALEANT PHARMS INTL	Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives	Feb, 2027 (4 years from now)

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
750MG	CAPSULE;ORAL	Prescription

36. Drug name - COMBIVENT RESPIMAT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9027967	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Mar, 2027 (4 years from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.1MG BASE/INH;0.02MG/INH	SPRAY, METERED;INHALATION	Prescription

37. Drug name - CONTRAVE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107837	NALPROPION	Sustained release formulation of naltrexone	Jun, 2027 (4 years from now)
US8722085	NALPROPION	Methods for administering weight loss medications	Nov, 2027 (5 years from now)
US8318788	NALPROPION	Layered pharmaceutical formulations	Nov, 2027 (5 years from now)
US10307376	NALPROPION	Methods for administering weight loss medications	Nov, 2027 (5 years from now)
US9125868	NALPROPION	Methods for administering weight loss medications	Nov, 2027 (5 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity; Use of naltrexone and bupropion based on an escalating dose schedule; Use of naltrexone and bupropion in a layered formulation for chronic weight management for affecting weight loss

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
90MG;8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

38. Drug name - CORLANOR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7867996 (Pediatric)	AMGEN INC	γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it	Jun, 2027 (4 years from now)

Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 7.5MG BASE	TABLET;ORAL	Prescription

39. Drug name - CRESEMBA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603280	ASTELLAS	Active ingredient containing stabilised solid medicinal forms and methods for the production thereof	Sep, 2027 (4 years from now)
US10206879	ASTELLAS	Active ingredient containing stabilised solid forms and method for the production thereof	Sep, 2027 (4 years from now)

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
186MG	CAPSULE;ORAL	Prescription

40. Drug name - DAKLINZA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9421192	BRISTOL-MYERS SQUIBB	Hepatitis C virus inhibitors	Aug, 2027 (4 years from now)
US8642025	BRISTOL-MYERS SQUIBB	Hepatitis C virus inhibitors	Aug, 2027 (4 years from now)
CN101558059B	BRISTOL-MYERS SQUIBB	Hepatitis C Virus Inhibitor	Aug, 2027 (4 years from now)
CN104447707A	BRISTOL-MYERS SQUIBB	Hepatitis C Virus Inhibitors	Aug, 2027 (4 years from now)
CN101558059A	BRISTOL-MYERS SQUIBB	Hepatitis C Virus Inhibitors	Aug, 2027 (4 years from now)
CN104447707B	BRISTOL-MYERS SQUIBB	Hepatitis C Virus Inhibitors	Aug, 2027 (4 years from now)
EP2784075A1	BRISTOL-MYERS SQUIBB	Hepatitis C Virus Inhibitors	Aug, 2027 (4 years from now)
EP2784075B1	BRISTOL-MYERS SQUIBB	Hepatitis C Virus Inhibitors	Aug, 2027 (4 years from now)
EP3042901A1	BRISTOL-MYERS SQUIBB	Hepatitis C Virus Inhibitors	Aug, 2027 (4 years from now)
EP3042901B1	BRISTOL-MYERS SQUIBB	Hepatitis C Virus Inhibitors	Aug, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900566	BRISTOL-MYERS SQUIBB	Hepatitis C virus inhibitors	Aug, 2027 (4 years from now)

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

Treatment: Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; method of inhibiting hepatitis c virus

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 30MG BASE	TABLET;ORAL	Discontinued
EQ 60MG BASE	TABLET;ORAL	Discontinued
EQ 90MG BASE	TABLET;ORAL	Discontinued

41. Drug name - DEXILANT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7790755 (Pediatric)	TAKEDA PHARMS USA	Controlled release preparation	Feb, 2027 (4 years from now)
US8105626 (Pediatric)	TAKEDA PHARMS USA	Granules containing acid-unstable chemical in large amount	Mar, 2027 (4 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
30MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription
60MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

42. Drug name - DIFICID

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7863249	CUBIST PHARMS LLC	Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof	Jul, 2027 (4 years from now)
US7378508	CUBIST PHARMS LLC	Polymorphic crystalline forms of tiacumicin B	Jul, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7906489	CUBIST PHARMS LLC	18-membered macrocycles and analogs thereof	Mar, 2027 (4 years from now)
US8859510	CUBIST PHARMS LLC	Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof	Jul, 2027 (4 years from now)
US7863249	CUBIST PHARMS LLC	Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof	Jul, 2027 (4 years from now)
US7906489 (Pediatric)	CUBIST PHARMS LLC	18-membered macrocycles and analogs thereof	Sep, 2027 (4 years from now)

Drugs and Companies using FIDAXOMICIN ingredient

Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG	TABLET;ORAL	Prescription

43. Drug name - DOVATO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Oct, 2027 (5 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 50MG BASE;300MG	TABLET;ORAL	Prescription

44. Drug name - DSUVIA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744129	ACELRX PHARMS	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain	Jan, 2027 (4 years from now)
US8252329	ACELRX PHARMS	Bioadhesive drug formulations for oral transmucosal delivery	Jan, 2027 (4 years from now)
US8778393	ACELRX PHARMS	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain	Jan, 2027 (4 years from now)
US8252328	ACELRX PHARMS	Bioadhesive drug formulations for oral transmucosal delivery	Jan, 2027 (4 years from now)
US10245228	ACELRX PHARMS	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain	Jan, 2027 (4 years from now)
US10507180	ACELRX PHARMS	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain	Jan, 2027 (4 years from now)
US8535714	ACELRX PHARMS	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain	Jan, 2027 (4 years from now)
US8865211	ACELRX PHARMS	Bioadhesive drug formulations for oral transmucosal delivery	Jan, 2027 (4 years from now)
US8778394	ACELRX PHARMS	Small-volume oral transmucosal dosage forms	Jan, 2027 (4 years from now)
US10342762	ACELRX PHARMS	Small-volume oral transmucosal dosage forms	Jan, 2027 (4 years from now)
US8226978	ACELRX PHARMS	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain	Jan, 2027 (4 years from now)
US9320710	ACELRX PHARMS	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain	Jan, 2027 (4 years from now)
US8231900	ACELRX PHARMS	Small-volume oral transmucosal dosage	Jan, 2027 (4 years from now)

Drugs and Companies using SUFENTANIL CITRATE ingredient

Treatment: Treatment of acute pain

Dosage: TABLET;SUBLINGUAL

Strength	Dosage	Availability
EQ 0.03MG BASE	TABLET;SUBLINGUAL	Prescription

45. Drug name - DUAKLIR PRESSAIR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8051851	ASTRAZENECA	Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler	Apr, 2027 (4 years from now)

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

Strength	Dosage	Availability
0.4MG/INH;0.012MG/INH	POWDER, METERED;INHALATION	Prescription

46. Drug name - DUAVEE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7683051	WYETH PHARMS	Crystalline polymorph of bazedoxifene acetate	Mar, 2027 (4 years from now)

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE;0.45MG	TABLET;ORAL	Prescription

47. Drug name - DUETACT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700128	TAKEDA PHARMS USA	Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester	Jan, 2027 (4 years from now)

Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG;30MG	TABLET;ORAL	Prescription
4MG;30MG	TABLET;ORAL	Prescription

48. Drug name - DURYSTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8206737	ALLERGAN INC	Hypotensive lipid-containing biodegradable intraocular implants and related methods	Apr, 2027 (4 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

Strength	Dosage	Availability
10MCG	IMPLANT;OPHTHALMIC	Prescription

49. Drug name - DYANAVEL XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086087	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (4 years from now)
US8597684	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (4 years from now)
US8883217	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (4 years from now)
US8747902	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (4 years from now)
US9675703	TRIS PHARMA INC	Modified release formulations containing drug - ion exchange resin complexes	Mar, 2027 (4 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
2MG/ML;EQ 0.5MG BASE/ML	SUSPENSION, EXTENDED RELEASE;ORAL	Prescription

50. Drug name - DYANAVEL XR 10

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8337890	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (4 years from now)
US9675704	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (4 years from now)
US8747902	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (4 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
8MG;EQ 2MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
12MG;EQ 3MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
16MG;EQ 4MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
4MG;EQ 1MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

51. Drug name - DYLOJECT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946292	JAVELIN PHARMS INC	Formulations of low dose diclofenac and beta-cyclodextrin	Mar, 2027 (4 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Management of pain

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
37.5MG/ML (37.5MG/ML)	SOLUTION;INTRAVENOUS	Discontinued

52. Drug name - EDLUAR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597281	MYLAN SPECIALITY LP	Pharmaceutical formulations useful in the treatment of insomnia	Apr, 2027 (4 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

Strength	Dosage	Availability
5MG	TABLET;SUBLINGUAL	Prescription
10MG	TABLET;SUBLINGUAL	Prescription

53. Drug name - ELEPSIA XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8163306	TRIPOINT	Oral drug delivery system	Sep, 2027 (4 years from now)
US8431156	TRIPOINT	Pharmaceutical composition	Oct, 2027 (5 years from now)
US8470367	TRIPOINT	Oral drug delivery system	Oct, 2027 (5 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
1.5GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

54. Drug name - EMBEDA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7682634	ALPHARMA PHARMS	Pharmaceutical compositions	Jun, 2027 (4 years from now)
US7682633	ALPHARMA PHARMS	Pharmaceutical composition	Jun, 2027 (4 years from now)
US8158156	ALPHARMA PHARMS	Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist	Jun, 2027 (4 years from now)
US8846104	ALPHARMA PHARMS	Pharmaceutical compositions for the deterrence and/or prevention of abuse	Jun, 2027 (4 years from now)
US8877247	ALPHARMA PHARMS	Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist	Jun, 2027 (4 years from now)
US7815934	ALPHARMA PHARMS	Sequestering subunit and related compositions and methods	Dec, 2027 (5 years from now)

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatement by orally administering an intact composition as claimed.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
20MG;0.8MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
30MG;1.2MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
50MG;2MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
60MG;2.4MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
80MG;3.2MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
100MG;4MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued

55. Drug name - EMEND

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132	MERCK	Pharmaceutical composition of a tachykinin receptor antagonist	Sep, 2027 (4 years from now)

Drugs and Companies using APREPITANT ingredient

Treatment: Prevention of postoperative nausea and vomiting; for the prevention of nausea and vomiting associated with chemotherapy

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
40MG	CAPSULE;ORAL	Discontinued
80MG	CAPSULE;ORAL	Prescription
125MG	CAPSULE;ORAL	Prescription

56. Drug name - EMEND

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132	MSD MERCK CO	Pharmaceutical composition of a tachykinin receptor antagonist	Sep, 2027 (4 years from now)

Drugs and Companies using APREPITANT ingredient

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

Strength	Dosage	Availability
125MG/KIT	FOR SUSPENSION;ORAL	Prescription

57. Drug name - EMPAVELI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9169307	APELLIS PHARMS	Potent compstatin analogs	Nov, 2027 (5 years from now)
US7888323	APELLIS PHARMS	Potent compstatin analogs	Dec, 2027 (5 years from now)
US7989589	APELLIS PHARMS	Compstatin analogs with improved activity	Dec, 2027 (5 years from now)

Drugs and Companies using PEGCETACOPLAN ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
1080MG/20ML (54MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

58. Drug name - ENTRESTO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8877938	NOVARTIS PHARMS CORP	Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations	May, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9388134 (Pediatric)	NOVARTIS PHARMS CORP	Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations	May, 2027 (4 years from now)
US8877938 (Pediatric)	NOVARTIS PHARMS CORP	Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations	Nov, 2027 (5 years from now)

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
24MG;26MG	TABLET;ORAL	Prescription
49MG;51MG	TABLET;ORAL	Prescription
97MG;103MG	TABLET;ORAL	Prescription

59. Drug name - EPIDUO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8445543	GALDERMA LABS LP	Combinations of adapalene and benzoyl peroxide for treating acne lesions	Jul, 2027 (4 years from now)
US8071644	GALDERMA LABS LP	Combinations of adapalene and benzoyl peroxide for treating acne lesions	Jul, 2027 (4 years from now)
US8129362	GALDERMA LABS LP	Combination/association of adapalene and benzoyl peroxide for treating acne lesions	Jul, 2027 (4 years from now)
US8080537	GALDERMA LABS LP	Combinations of adapalene and benzoyl peroxide for treating acne lesions	Jul, 2027 (4 years from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
0.1%;2.5%	GEL;TOPICAL	Prescription

60. Drug name - ERLEADA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9388159	JANSSEN BIOTECH	Substituted diazaspiroalkanes as androgen receptor modulators	Mar, 2027 (4 years from now)
CN101454002B	JANSSEN BIOTECH	For The Treatment Of Prostate Cancer And The Androgen Receptor-Related Disease Of Androgen Receptor Modulators	Mar, 2027 (4 years from now)
CN101454002A	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP2656842A3	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP2656841B1	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP2004181A2	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP2656842A2	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP3412290A1	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP2656841A1	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP3100727B1	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP3412290B1	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP2004181A4	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP3100727A1	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP2004181B1	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP2656842B1	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP2368550B1	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
EP2368550A1	JANSSEN BIOTECH	Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases	Mar, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987261	JANSSEN BIOTECH	Substituted diazaspiroalkanes as androgen receptor modulators	Mar, 2027 (4 years from now)
US8802689	JANSSEN BIOTECH	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases	Mar, 2027 (4 years from now)

Drugs and Companies using APALUTAMIDE ingredient

Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); treatment of metastatic castration-sensitive prostate cancer (mcspc)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
60MG	TABLET;ORAL	Prescription

61. Drug name - ESBRIET

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7767700	GENENTECH INC	Method of providing pirfenidone therapy to a patient	Dec, 2027 (5 years from now)
US8420674	GENENTECH INC	Method of providing pirfenidone therapy to a patient	Dec, 2027 (5 years from now)
US7696236	GENENTECH INC	Method of providing pirfenidone therapy to a patient	Dec, 2027 (5 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Treatment: Pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
267MG	CAPSULE;ORAL	Prescription

62. Drug name - EUCRISA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501712	ANACOR PHARMS INC	Boron-containing small molecules as anti-inflammatory agents	Feb, 2027 (4 years from now)
US9682092	ANACOR PHARMS INC	Boron-containing small molecules as anti-inflammatory agents	Feb, 2027 (4 years from now)
US8501712 (Pediatric)	ANACOR PHARMS INC	Boron-containing small molecules as anti-inflammatory agents	Aug, 2027 (4 years from now)
US9682092 (Pediatric)	ANACOR PHARMS INC	Boron-containing small molecules as anti-inflammatory agents	Aug, 2027 (4 years from now)

Drugs and Companies using CRISABOROLE ingredient

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

Strength	Dosage	Availability
2%	OINTMENT;TOPICAL	Prescription

63. Drug name - EVZIO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108	KALEO INC	Medicament delivery device having an electronic circuit system	Feb, 2027 (4 years from now)
US8206360	KALEO INC	Devices, systems and methods for medicament delivery	Feb, 2027 (4 years from now)
US9724471	KALEO INC	Devices, systems, and methods for medicament delivery	May, 2027 (4 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
0.4MG/0.4ML (0.4MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

64. Drug name - EVZIO (AUTOINJECTOR)

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108	KALEO INC	Medicament delivery device having an electronic circuit system	Feb, 2027 (4 years from now)
US8206360	KALEO INC	Devices, systems and methods for medicament delivery	Feb, 2027 (4 years from now)
US9724471	KALEO INC	Devices, systems, and methods for medicament delivery	May, 2027 (4 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
2MG/0.4ML (2MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

65. Drug name - FANAPT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586610	VANDA PHARMS INC	Methods for the administration of iloperidone	Nov, 2027 (5 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1MG	TABLET;ORAL	Prescription
2MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
6MG	TABLET;ORAL	Prescription
8MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
12MG	TABLET;ORAL	Prescription

66. Drug name - FARXIGA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501698	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Jun, 2027 (4 years from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

67. Drug name - FIBRICOR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7741374	ATHENA	Methods of use of fenofibric acid	Aug, 2027 (4 years from now)
US7741373	ATHENA	Methods of use of fenofibric acid	Aug, 2027 (4 years from now)
US7915247	ATHENA	Methods of use of fenofibric acid	Aug, 2027 (4 years from now)
US7569612	ATHENA	Methods of use of fenofibric acid	Aug, 2027 (4 years from now)

Drugs and Companies using FENOFIBRIC ACID ingredient

Treatment: Adjunctive therapy to diet in patients with mixed dyslipidemia; adjunctive therapy to diet in patients with elevated cholesterol and/or lipid levels; Adjunctive therapy to diet to patients with hypertriglyceridemia; Adjunctive therapy to diet in patients with hyperlipidemias; adjunctive therapy to diet in patients with mixed dyslipidemia; adjunctive therapy to diet to patients with hypertriglyceridemia; Adjunctive therapy to diet in patients with hyperlipidemias

Dosage: TABLET;ORAL

Strength	Dosage	Availability
35MG	TABLET;ORAL	Discontinued
105MG	TABLET;ORAL	Prescription

68. Drug name - FINACEA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700076	LEO PHARMA AS	Penetrating pharmaceutical foam	Sep, 2027 (4 years from now)
US10117812	LEO PHARMA AS	Foamable composition combining a polar solvent and a hydrophobic carrier	Oct, 2027 (5 years from now)
US9265725	LEO PHARMA AS	Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof	Dec, 2027 (5 years from now)

Drugs and Companies using AZELAIC ACID ingredient

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Dosage	Availability
15%	AEROSOL, FOAM;TOPICAL	Prescription

69. Drug name - FLOLIPID

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10300041	TCG FLUENT PHARMA	Liquid oral simvastatin compositions	Apr, 2027 (4 years from now)

Drugs and Companies using SIMVASTATIN ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
20MG/5ML	SUSPENSION;ORAL	Prescription
40MG/5ML	SUSPENSION;ORAL	Prescription

70. Drug name - FORFIVO XL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7674479	ALMATICA	Sustained-release bupropion and bupropion/mecamylamine tablets	Jun, 2027 (4 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
450MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

71. Drug name - GALAFOLD

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10383864	AMICUS THERAP US	Methods for treatment of Fabry disease	May, 2027 (4 years from now)
US9000011	AMICUS THERAP US	Methods for treatment of Fabry disease	May, 2027 (4 years from now)
US9480682	AMICUS THERAP US	Methods for treatment of Fabry disease	May, 2027 (4 years from now)
US10406143	AMICUS THERAP US	Methods for treatment of fabry disease	May, 2027 (4 years from now)
US9987263	AMICUS THERAP US	Methods for treatment of Fabry disease	May, 2027 (4 years from now)
US11241422	AMICUS THERAP US	Methods for treatment of Fabry disease	May, 2027 (4 years from now)

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 123MG BASE	CAPSULE;ORAL	Prescription

72. Drug name - GENOSYL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560076	VERO BIOTECH	Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)	Apr, 2027 (4 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: NA

Dosage: GAS;INHALATION

Strength	Dosage	Availability
800PPM	GAS;INHALATION	Prescription

73. Drug name - GENVOYA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176220 (Pediatric)	GILEAD SCIENCES INC	4-oxoquinoline compound and use thereof as pharmaceutical agent	Feb, 2027 (4 years from now)
US8981103 (Pediatric)	GILEAD SCIENCES INC	Stable crystal of 4-oxoquinoline compound	Apr, 2027 (4 years from now)
US7635704 (Pediatric)	GILEAD SCIENCES INC	Stable crystal of 4-oxoquinoline compound	Apr, 2027 (4 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;150MG;200MG;EQ 10MG BASE	TABLET;ORAL	Prescription

74. Drug name - GILENYA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9187405	NOVARTIS	S1P receptor modulators for treating relasping-remitting multiple sclerosis	Jun, 2027 (4 years from now)
US9187405 (Pediatric)	NOVARTIS	S1P receptor modulators for treating relasping-remitting multiple sclerosis	Dec, 2027 (5 years from now)
US10543179	NOVARTIS	Dosage regimen of an S1P receptor modulator	Dec, 2027 (5 years from now)

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 0.25MG BASE	CAPSULE;ORAL	Prescription
EQ 0.5MG BASE	CAPSULE;ORAL	Prescription

75. Drug name - GILOTRIF

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539258 (Pediatric)	BOEHRINGER INGELHEIM	Quinazoline derivatives for the treatment of cancer diseases	May, 2027 (4 years from now)

Drugs and Companies using AFATINIB DIMALEATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 30MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription

76. Drug name - GLYXAMBI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938	BOEHRINGER INGELHEIM	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	Apr, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173859	BOEHRINGER INGELHEIM	Uses of DPP IV inhibitors	May, 2027 (4 years from now)
US8673927	BOEHRINGER INGELHEIM	Uses of DPP-IV inhibitors	May, 2027 (4 years from now)
US11033552	BOEHRINGER INGELHEIM	DPP IV inhibitor formulations	May, 2027 (4 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG;5MG	TABLET;ORAL	Prescription
25MG;5MG	TABLET;ORAL	Prescription

77. Drug name - HALAVEN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46965	EISAI INC	Intermediates for the preparation of analogs of Halichondrin B	Jan, 2027 (4 years from now)

Drugs and Companies using ERIBULIN MESYLATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1MG/2ML (0.5MG/ML)	SOLUTION;INTRAVENOUS	Prescription

78. Drug name - HYSINGLA ER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492389	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9763933	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9775809	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9486412	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9084816	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9486413	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9770416	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9095614	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9095615	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9545380	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9492391	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9492390	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
20MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
40MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
60MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
80MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
100MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
120MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

79. Drug name - IBRANCE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47739	PFIZER	2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones	Mar, 2027 (4 years from now)

Drugs and Companies using PALBOCICLIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
75MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription
125MG	TABLET;ORAL	Prescription

80. Drug name - ICLUSIG

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8114874	TAKEDA PHARMS USA	Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors	Jan, 2027 (4 years from now)
EP2024366A4	TAKEDA PHARMS USA	Monocyclic Heteroaryl Compounds	May, 2027 (4 years from now)
EP2024366B1	TAKEDA PHARMS USA	Monocyclic Heteroaryl Compounds	May, 2027 (4 years from now)
EP2024366A2	TAKEDA PHARMS USA	Monocyclic Heteroaryl Compounds	May, 2027 (4 years from now)

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 10MG BASE	TABLET;ORAL	Prescription
EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 30MG BASE	TABLET;ORAL	Prescription
EQ 45MG BASE	TABLET;ORAL	Prescription

81. Drug name - ILUVIEN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871241	ALIMERA SCIENCES INC	Injectable sustained release delivery devices	Aug, 2027 (4 years from now)

Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient

Treatment: NA

Dosage: IMPLANT;INTRAVITREAL

Strength	Dosage	Availability
0.19MG	IMPLANT;INTRAVITREAL	Prescription

82. Drug name - IMBRUVICA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008309	PHARMACYCLICS INC	Inhibitors of bruton's tyrosine kinase	Nov, 2027 (5 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8563563	PHARMACYCLICS INC	Inhibitors of bruton's tyrosine kinase	Apr, 2027 (4 years from now)

Drugs and Companies using IBRUTINIB ingredient

Treatment: Treatment of waldenstrom's macroglobulinemia; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma with 17p deletion

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
70MG	CAPSULE;ORAL	Prescription
140MG	CAPSULE;ORAL	Prescription

83. Drug name - IMCIVREE

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9458195	RHYTHM	Melanocortin receptor ligands	Oct, 2027 (5 years from now)
US8039435	RHYTHM	Melanocortin receptor ligands	Oct, 2027 (5 years from now)

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 10MG/ML BASE (EQ 10MG/ML BASE)	SOLUTION;SUBCUTANEOUS	Prescription

84. Drug name - IMPLANON

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10821277	ORGANON	Kit for and method of assembling an applicator for inserting an implant	May, 2027 (4 years from now)
US8722037	ORGANON	X-ray visible drug delivery device	Sep, 2027 (4 years from now)

Drugs and Companies using ETONOGESTREL ingredient

Treatment: NA

Dosage: IMPLANT;IMPLANTATION

Strength	Dosage	Availability
68MG/IMPLANT	IMPLANT;IMPLANTATION	Prescription

85. Drug name - INCRUSE ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7488827	GLAXO GRP ENGLAND	Muscarinic acetylcholine receptor antagonists	Dec, 2027 (5 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310	GLAXO GRP ENGLAND	Medicament dispenser	Oct, 2027 (4 years from now)
US8113199	GLAXO GRP ENGLAND	Counter for use with a medicament dispenser	Oct, 2027 (5 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
EQ 62.5MCG BASE/INH	POWDER;INHALATION	Prescription

86. Drug name - INGREZZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357697	NEUROCRINE	Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto	Nov, 2027 (5 years from now)

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 40MG BASE	CAPSULE;ORAL	Prescription
EQ 60MG BASE	CAPSULE;ORAL	Prescription
EQ 80MG BASE	CAPSULE;ORAL	Prescription

87. Drug name - INJECTAFER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895612	AM REGENT	Methods and compositions for administration of iron	Jan, 2027 (4 years from now)

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Treatment: Method of treatment of iron-related conditions with at least 0.6 grams of elemental iron via an iron carbohydrate complex, with a substantially non-immunogenic carbohydrate component, in about 15 minutes or less.; method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by administering iv at least about 0.6 g of iron as ferric carboxymaltose in about 15 min or less; method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering at least about 0.6 grams of iron as ferric carboxymaltose in about 15 minutes or less

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1GM IRON/20ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
750MG IRON/15ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
100MG IRON/2ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
500MG IRON/10ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription

88. Drug name - INTERMEZZO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7658945	PURDUE PHARMA	Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof	Apr, 2027 (4 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Treatment: Method for treating insomnia

Dosage: TABLET;SUBLINGUAL

Strength	Dosage	Availability
1.75MG	TABLET;SUBLINGUAL	Discontinued
3.5MG	TABLET;SUBLINGUAL	Discontinued

89. Drug name - INVOKAMET

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2027 (4 years from now)
US8513202	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	Dec, 2027 (5 years from now)
CN101573368A	JANSSEN PHARMS	A Novel Crystalline Form Of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate With Favourable Characteristics Has Its X-Ray Powder Diffraction Pattern And/Or By Its Infrared Spectrum.	Dec, 2027 (5 years from now)
CN101573368B	JANSSEN PHARMS	Crystalline 1 - ([Beta] - D-Glucopyranosyl) - 4-Methyl-3 - [5 - (4-Fluorophenyl) - 2-Thienyl] Benzene Hemihydrate	Dec, 2027 (5 years from now)
IN200903871P4	JANSSEN PHARMS	Crystalline Form Of 1-(B-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene Hemihydrate	Dec, 2027 (5 years from now)
IN286412B	JANSSEN PHARMS	Crystalline Form Of 1-(B-Dglucopyranosyl)- 4-Methyl-3-[5-(4- Fluorophenyl)-2- Thienylmethyl] Benzene Hemihydrate	Dec, 2027 (5 years from now)
EP2102224B1	JANSSEN PHARMS	Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate	Dec, 2027 (5 years from now)
EP2102224B2	JANSSEN PHARMS	Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate	Dec, 2027 (5 years from now)
EP2102224A1	JANSSEN PHARMS	Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate	Dec, 2027 (5 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG;500MG	TABLET;ORAL	Prescription
50MG;1GM	TABLET;ORAL	Prescription
150MG;500MG	TABLET;ORAL	Prescription
150MG;1GM	TABLET;ORAL	Prescription

90. Drug name - INVOKAMET XR

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2027 (4 years from now)
US8513202	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	Dec, 2027 (5 years from now)
CN101573368A	JANSSEN PHARMS	A Novel Crystalline Form Of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate With Favourable Characteristics Has Its X-Ray Powder Diffraction Pattern And/Or By Its Infrared Spectrum.	Dec, 2027 (5 years from now)
CN101573368B	JANSSEN PHARMS	Crystalline 1 - ([Beta] - D-Glucopyranosyl) - 4-Methyl-3 - [5 - (4-Fluorophenyl) - 2-Thienyl] Benzene Hemihydrate	Dec, 2027 (5 years from now)
IN200903871P4	JANSSEN PHARMS	Crystalline Form Of 1-(B-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene Hemihydrate	Dec, 2027 (5 years from now)
IN286412B	JANSSEN PHARMS	Crystalline Form Of 1-(B-Dglucopyranosyl)- 4-Methyl-3-[5-(4- Fluorophenyl)-2- Thienylmethyl] Benzene Hemihydrate	Dec, 2027 (5 years from now)
EP2102224B1	JANSSEN PHARMS	Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate	Dec, 2027 (5 years from now)
EP2102224B2	JANSSEN PHARMS	Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate	Dec, 2027 (5 years from now)
EP2102224A1	JANSSEN PHARMS	Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate	Dec, 2027 (5 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
50MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
50MG;500MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
150MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
150MG;500MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

91. Drug name - INVOKANA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2027 (4 years from now)
US8513202	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	Dec, 2027 (5 years from now)
CN101573368A	JANSSEN PHARMS	A Novel Crystalline Form Of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate With Favourable Characteristics Has Its X-Ray Powder Diffraction Pattern And/Or By Its Infrared Spectrum.	Dec, 2027 (5 years from now)
CN101573368B	JANSSEN PHARMS	Crystalline 1 - ([Beta] - D-Glucopyranosyl) - 4-Methyl-3 - [5 - (4-Fluorophenyl) - 2-Thienyl] Benzene Hemihydrate	Dec, 2027 (5 years from now)
IN200903871P4	JANSSEN PHARMS	Crystalline Form Of 1-(B-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene Hemihydrate	Dec, 2027 (5 years from now)
IN286412B	JANSSEN PHARMS	Crystalline Form Of 1-(B-Dglucopyranosyl)- 4-Methyl-3-[5-(4- Fluorophenyl)-2- Thienylmethyl] Benzene Hemihydrate	Dec, 2027 (5 years from now)
EP2102224B1	JANSSEN PHARMS	Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate	Dec, 2027 (5 years from now)
EP2102224B2	JANSSEN PHARMS	Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate	Dec, 2027 (5 years from now)
EP2102224A1	JANSSEN PHARMS	Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate	Dec, 2027 (5 years from now)

Drugs and Companies using CANAGLIFLOZIN ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Prescription

92. Drug name - JAKAFI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598257	INCYTE CORP	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors	Dec, 2027 (5 years from now)
US8415362	INCYTE CORP	Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors	Dec, 2027 (5 years from now)
EP1966202B1	INCYTE CORP	Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors	Aug, 2027 (4 years from now)
EP1966202A1	INCYTE CORP	Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors	Aug, 2027 (4 years from now)

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 10MG BASE	TABLET;ORAL	Prescription
EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 25MG BASE	TABLET;ORAL	Prescription

93. Drug name - JANUMET

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7326708 (Pediatric)	MERCK SHARP DOHME	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	May, 2027 (4 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1GM;EQ 50MG BASE	TABLET;ORAL	Prescription
500MG;EQ 50MG BASE	TABLET;ORAL	Prescription

94. Drug name - JANUMET XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7326708 (Pediatric)	MERCK SHARP DOHME	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	May, 2027 (4 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
1GM;EQ 50MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
1GM;EQ 100MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
500MG;EQ 50MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

95. Drug name - JANUVIA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7326708 (Pediatric)	MERCK SHARP DOHME	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	May, 2027 (4 years from now)

Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 25MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE	TABLET;ORAL	Prescription
EQ 100MG BASE	TABLET;ORAL	Prescription

96. Drug name - JARDIANCE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938	BOEHRINGER INGELHEIM	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	Apr, 2027 (4 years from now)

Drugs and Companies using EMPAGLIFLOZIN ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
25MG	TABLET;ORAL	Prescription

97. Drug name - JENTADUETO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673927	BOEHRINGER INGELHEIM	Uses of DPP-IV inhibitors	May, 2027 (4 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2.5MG;1GM	TABLET;ORAL	Prescription
2.5MG;500MG	TABLET;ORAL	Prescription
2.5MG;850MG	TABLET;ORAL	Prescription

98. Drug name - JENTADUETO XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673927	BOEHRINGER INGELHEIM	Uses of DPP-IV inhibitors	May, 2027 (4 years from now)
US9173859	BOEHRINGER INGELHEIM	Uses of DPP IV inhibitors	May, 2027 (4 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

99. Drug name - JULUCA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Oct, 2027 (5 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 50MG BASE;EQ 25MG BASE	TABLET;ORAL	Prescription

100. Drug name - JUXTAPID

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7932268	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects	Aug, 2027 (4 years from now)

Drugs and Companies using LOMITAPIDE MESYLATE ingredient

Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 5MG BASE	CAPSULE;ORAL	Prescription
EQ 10MG BASE	CAPSULE;ORAL	Prescription
EQ 20MG BASE	CAPSULE;ORAL	Prescription
EQ 30MG BASE	CAPSULE;ORAL	Prescription
EQ 40MG BASE	CAPSULE;ORAL	Discontinued
EQ 60MG BASE	CAPSULE;ORAL	Discontinued

101. Drug name - KALYDECO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7495103	VERTEX PHARMS INC	Modulators of ATP-binding cassette transporters	May, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324242	VERTEX PHARMS INC	Modulators of ATP-binding cassette transporters	Aug, 2027 (4 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; method of treating cystic fibrosis; treatment of cystic fibrosis using ivacaftor in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
25MG/PACKET	GRANULE;ORAL	Prescription
50MG/PACKET	GRANULE;ORAL	Prescription
75MG/PACKET	GRANULE;ORAL	Prescription

102. Drug name - KALYDECO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7495103	VERTEX PHARMS	Modulators of ATP-binding cassette transporters	May, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324242	VERTEX PHARMS	Modulators of ATP-binding cassette transporters	Aug, 2027 (4 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Method of treating cystic fibrosis; method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG	TABLET;ORAL	Prescription

103. Drug name - KARBINAL ER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522191	AYTU	Modified release formulations containing drug—ion exchange resin complexes	Jun, 2027 (4 years from now)

Drugs and Companies using CARBINOXAMINE MALEATE ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
4MG/5ML	SUSPENSION, EXTENDED RELEASE;ORAL	Prescription

104. Drug name - KLISYRI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10323001	ALMIRALL	Compositions for modulating a kinase cascade and methods of use thereof	Dec, 2027 (5 years from now)

Drugs and Companies using TIRBANIBULIN ingredient

Treatment: NA

Dosage: OINTMENT;TOPICAL

Strength	Dosage	Availability
1%	OINTMENT;TOPICAL	Prescription

105. Drug name - KORSUVA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10793596	CARA THERAP	Synthetic peptide amides	Nov, 2027 (5 years from now)
US8536131	CARA THERAP	Synthetic peptide amides and dimers thereof	Nov, 2027 (5 years from now)
US10017536	CARA THERAP	Synthetic peptide amides and dimers thereof	Nov, 2027 (5 years from now)
US7402564	CARA THERAP	Synthetic peptide amides	Nov, 2027 (5 years from now)
US7713937	CARA THERAP	Synthetic peptide amides and dimeric forms thereof	Nov, 2027 (5 years from now)
US7727963	CARA THERAP	Synthetic peptide amides	Nov, 2027 (5 years from now)
CN101627049A	CARA THERAP	Synthetic Phthalamide	Nov, 2027 (5 years from now)
CN101627049B	CARA THERAP	Synthetic Phthalamide	Nov, 2027 (5 years from now)
CN101535336B	CARA THERAP	Synthesizing Phthalic Amide And The Dimer	Nov, 2027 (5 years from now)
CN101535336A	CARA THERAP	Synthetic Peptide Amides And Dimers Thereof	Nov, 2027 (5 years from now)
IN200903250P4	CARA THERAP	Synthetic Peptide Amides	Nov, 2027 (5 years from now)
IN298634B	CARA THERAP	Synthetic Peptide Amides And Dimers Thereof	Nov, 2027 (5 years from now)
IN298624B	CARA THERAP	Synthetic Peptide Amides	Nov, 2027 (5 years from now)
IN200903251P4	CARA THERAP	Synthetic Peptide Amides And Dimers Thereof	Nov, 2027 (5 years from now)
EP2064228A2	CARA THERAP	Synthetic Peptide Amides	Nov, 2027 (5 years from now)
EP2064228B1	CARA THERAP	Synthetic Peptide Amides	Nov, 2027 (5 years from now)
EP2079756A2	CARA THERAP	Synthetic Peptide Amides And Dimers Thereof	Nov, 2027 (5 years from now)
EP2079756B1	CARA THERAP	Synthetic Peptide Amides And Dimers Thereof	Nov, 2027 (5 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8217007	CARA THERAP	Synthetic peptide amides	Nov, 2027 (5 years from now)
US8236766	CARA THERAP	Uses of synthetic peptide amides	Nov, 2027 (5 years from now)
US8486894	CARA THERAP	Synthetic peptide amides and dimeric forms thereof	Nov, 2027 (5 years from now)
US9334305	CARA THERAP	Synthetic peptide amides and dimers thereof	Nov, 2027 (5 years from now)
US9359399	CARA THERAP	Synthetic peptide amides	Nov, 2027 (5 years from now)
US10138270	CARA THERAP	Synthetic peptide amides	Nov, 2027 (5 years from now)

Drugs and Companies using DIFELIKEFALIN ACETATE ingredient

Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

106. Drug name - KYBELLA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7622130	KYTHERA BIOPHARMS	Methods and compositions for the non-surgical removal of fat	Dec, 2027 (5 years from now)
US7754230	KYTHERA BIOPHARMS	Methods and related compositions for reduction of fat	Dec, 2027 (5 years from now)

Drugs and Companies using DEOXYCHOLIC ACID ingredient

Treatment: Method for reduction of submental fat

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
20MG/2ML (10MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

107. Drug name - KYNAMRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7511131	KASTLE THERAPS LLC	Antisense modulation of apolipoprotein B expression	Jan, 2027 (4 years from now)

Drugs and Companies using MIPOMERSEN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
200MG/ML (200MG/ML)	SOLUTION;SUBCUTANEOUS	Discontinued

108. Drug name - KYPROLIS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7737112	ONYX THERAP	Composition for enzyme inhibition	Dec, 2027 (5 years from now)

Drugs and Companies using CARFILZOMIB ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
10MG/VIAL	POWDER;INTRAVENOUS	Prescription
30MG/VIAL	POWDER;INTRAVENOUS	Prescription
60MG/VIAL	POWDER;INTRAVENOUS	Prescription

109. Drug name - LASTACAFT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617695	ALLERGAN	Ophthalmic compositions containing alcaftadine	Mar, 2027 (4 years from now)
US8664215	ALLERGAN	Ocular allergy treatments with alcaftadine	Dec, 2027 (5 years from now)

Drugs and Companies using ALCAFTADINE ingredient

Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.25%	SOLUTION/DROPS;OPHTHALMIC	Over the counter

110. Drug name - LENVIMA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006256	EISAI INC	Antitumor agent for thyroid cancer	Jul, 2027 (4 years from now)

Drugs and Companies using LENVATINIB MESYLATE ingredient

Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 4MG BASE	CAPSULE;ORAL	Prescription
EQ 10MG BASE	CAPSULE;ORAL	Prescription

111. Drug name - LEQVIO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8809292	NOVARTIS	Compositions and methods for inhibiting expression of the PCSK9 gene	May, 2027 (4 years from now)
IN200806166P4	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
IN269138B	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2584047B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP3249052A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP3249052B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2835429A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP3578656A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2584048A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2584047A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2194128A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP3578656B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2584048B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2835429B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2194128B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222222	NOVARTIS	Compositions and methods for inhibiting expression of the PCSK9 gene	Dec, 2027 (5 years from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

112. Drug name - LETAIRIS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474752	GILEAD	Method for treating a pulmonary hypertension condition	Dec, 2027 (5 years from now)
US8377933	GILEAD	Method for treating a pulmonary hypertension condition	Dec, 2027 (5 years from now)

Drugs and Companies using AMBRISENTAN ingredient

Treatment: For the treatment of pulmonary hypertension (pah) in combination with tadalafil

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

113. Drug name - LEVITRA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8273876	BAYER HLTHCARE	Medicaments containing vardenafil hydrochloride trihydrate	Jul, 2027 (4 years from now)

Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient

Treatment: Treatement of erectiile dysfunction by administering a film-coated tablet

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 2.5MG BASE	TABLET;ORAL	Discontinued
EQ 5MG BASE	TABLET;ORAL	Discontinued
EQ 10MG BASE	TABLET;ORAL	Discontinued
EQ 20MG BASE	TABLET;ORAL	Discontinued

114. Drug name - LEXISCAN

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8106183	ASTELLAS	Process for preparing an A2A-adenosine receptor agonist and its polymorphs	Feb, 2027 (4 years from now)
EP1989214A1	ASTELLAS	Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs	Feb, 2027 (4 years from now)
EP1989214B1	ASTELLAS	Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs	Feb, 2027 (4 years from now)
EP1989214B8	ASTELLAS	Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs	Feb, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47301	ASTELLAS	Process for preparing an A2A-adenosine receptor agonist and its polymorphs	Feb, 2027 (4 years from now)

Drugs and Companies using REGADENOSON ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
0.4MG/5ML (0.08MG/ML)	SOLUTION;INTRAVENOUS	Prescription

115. Drug name - LUMIGAN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851504	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Jun, 2027 (4 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.01%	SOLUTION/DROPS;OPHTHALMIC	Prescription

116. Drug name - LYNPARZA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143241	ASTRAZENECA	DNA damage repair inhibitors for treatment of cancer	Aug, 2027 (4 years from now)
US8071579	ASTRAZENECA	DNA damage repair inhibitors for the treatment of cancer	Aug, 2027 (4 years from now)

Drugs and Companies using OLAPARIB ingredient

Treatment: Treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
50MG	CAPSULE;ORAL	Discontinued

117. Drug name - LYRICA CR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945620 (Pediatric)	UPJOHN	Solid pharmaceutical compositions containing pregabalin	May, 2027 (4 years from now)
US9144559 (Pediatric)	UPJOHN	Solid pharmaceutical compositions containing pregabalin	May, 2027 (4 years from now)
US10022447 (Pediatric)	UPJOHN	Solid pharmaceutical compositions containing pregabalin	May, 2027 (4 years from now)

Drugs and Companies using PREGABALIN ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
82.5MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
165MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
330MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

118. Drug name - MACRILEN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719	NOVO	Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds	Oct, 2027 (5 years from now)

Drugs and Companies using MACIMORELIN ACETATE ingredient

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin

Dosage: FOR SOLUTION;ORAL

Strength	Dosage	Availability
EQ 60MG BASE/POUCH	FOR SOLUTION;ORAL	Prescription

119. Drug name - MEKINIST

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7378423	NOVARTIS	Pyrimidine compound and medical use thereof	May, 2027 (4 years from now)

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.5MG	TABLET;ORAL	Prescription
EQ 1MG	TABLET;ORAL	Discontinued
EQ 2MG	TABLET;ORAL	Prescription

120. Drug name - MOXATAG

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8299052	PRAGMA	Pharmaceutical compositions and methods for improved bacterial eradication	May, 2027 (4 years from now)

Drugs and Companies using AMOXICILLIN ingredient

Treatment: Use of once-a-day amoxicillin product to treat tonsillitis and/or pharyngitis secondary to streptococcus pyogenes

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
775MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

121. Drug name - NEUPRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8246979	UCB INC	Transdermal delivery system for the administration of rotigotine	Sep, 2027 (4 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Treatment: Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; treatment of restless legs syndrome by application of claimed transdermal delivery system

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Dosage	Availability
1MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
2MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
3MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
4MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
6MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
8MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

122. Drug name - NEVANAC

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7834059	NOVARTIS	Topical nepafenac formulations	Jan, 2027 (4 years from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: Method of treating ocular inflammation

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.1%	SUSPENSION/DROPS;OPHTHALMIC	Prescription

123. Drug name - NEXAVAR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8877933	BAYER HLTHCARE	Thermodynamically stable form of a tosylate salt	Dec, 2027 (5 years from now)

Drugs and Companies using SORAFENIB TOSYLATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

124. Drug name - NEXICLON XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8337890	ATHENA	Modified release formulations containing drug-ion exchange resin complexes	Apr, 2027 (4 years from now)

Drugs and Companies using CLONIDINE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 0.17MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 0.26MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued

125. Drug name - NINLARO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8003819	TAKEDA PHARMS USA	Proteasome inhibitors	Aug, 2027 (4 years from now)
US8530694	TAKEDA PHARMS USA	Proteasome inhibitors	Aug, 2027 (4 years from now)
US7687662	TAKEDA PHARMS USA	Proteasome inhibitors	Aug, 2027 (4 years from now)
CN101772507B	TAKEDA PHARMS USA	Proteasome Inhibitors	Aug, 2027 (4 years from now)
CN102961387B	TAKEDA PHARMS USA	Proteasome Inhibitors	Aug, 2027 (4 years from now)
CN105837608A	TAKEDA PHARMS USA	Proteasome Inhibitor And Composition And Application Thereof	Aug, 2027 (4 years from now)
CN105837608B	TAKEDA PHARMS USA	Proteasome Inhibitors And Compositions And Uses Thereof	Aug, 2027 (4 years from now)
CN102961387A	TAKEDA PHARMS USA	Proteasome Inhibitors	Aug, 2027 (4 years from now)
CN101772507A	TAKEDA PHARMS USA	Proteasome Inhibitors	Aug, 2027 (4 years from now)
EP2178888A1	TAKEDA PHARMS USA	Proteasome Inhibitors	Aug, 2027 (4 years from now)
EP2178888B1	TAKEDA PHARMS USA	Proteasome Inhibitors	Aug, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871745	TAKEDA PHARMS USA	Proteasome inhibitors	Aug, 2027 (4 years from now)

Drugs and Companies using IXAZOMIB CITRATE ingredient

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 2.3MG BASE	CAPSULE;ORAL	Prescription
EQ 3MG BASE	CAPSULE;ORAL	Prescription
EQ 4MG BASE	CAPSULE;ORAL	Prescription

126. Drug name - NOURIANZ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318201	KYOWA KIRIN	Method of stabilizing diarylvinylene compound	Sep, 2027 (4 years from now)

Drugs and Companies using ISTRADEFYLLINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
20MG	TABLET;ORAL	Prescription
40MG	TABLET;ORAL	Prescription

127. Drug name - OCALIVA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE48286	INTERCEPT PHARMS INC	Steroids as agonists for FXR	Feb, 2027 (4 years from now)

Drugs and Companies using OBETICHOLIC ACID ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

128. Drug name - OLEPTRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7829120	ANGELINI PHARMA	Trazodone composition for once a day administration	Mar, 2027 (4 years from now)

Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient

Treatment: Method of treating depression

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
150MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
300MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

129. Drug name - ONGENTYS

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8907099	NEUROCRINE	Nitrocatechol derivatives as COMT inhibitors	May, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9745290	NEUROCRINE	Dosage regimen for COMT inhibitors	Oct, 2027 (5 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: Method of treating parkinson's disease

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE;ORAL	Prescription
50MG	CAPSULE;ORAL	Prescription

130. Drug name - ONIVYDE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8329213	IPSEN INC	Liposomes useful for drug delivery	Jan, 2027 (4 years from now)

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

Strength	Dosage	Availability
EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	INJECTABLE, LIPOSOMAL;INTRAVENOUS	Prescription

131. Drug name - ONPATTRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642076	ALNYLAM PHARMS INC	Lipid containing formulations	Oct, 2027 (5 years from now)

Drugs and Companies using PATISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

132. Drug name - ONSOLIS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597288	BDSI	Transmucosal delivery devices with enhanced uptake	Jul, 2027 (4 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Treatment: Management of breakthrough pain in patients with cancer

Dosage: FILM;BUCCAL

Strength	Dosage	Availability
EQ 0.2MG BASE	FILM;BUCCAL	Discontinued
EQ 0.4MG BASE	FILM;BUCCAL	Discontinued
EQ 0.6MG BASE	FILM;BUCCAL	Discontinued
EQ 0.8MG BASE	FILM;BUCCAL	Discontinued
EQ 1.2MG BASE	FILM;BUCCAL	Discontinued

133. Drug name - ONZETRA XSAIL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10124132	CURRAX	Nasal delivery	Mar, 2027 (4 years from now)
US10398859	CURRAX	Nasal delivery devices	Dec, 2027 (5 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; acute treatment of migraine

Dosage: POWDER;NASAL

Strength	Dosage	Availability
EQ 11MG BASE	POWDER;NASAL	Prescription

134. Drug name - OPANA ER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8808737	ENDO PHARMS	Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment	Jun, 2027 (4 years from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Treatment: Method of administration of controlled release oxymorphone

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
7.5MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
10MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
15MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
20MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
30MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
40MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

135. Drug name - OPSUMIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265762	ACTELION	Stable pharmaceutical compositions comprising a pyrimidine-sulfamide	May, 2027 (4 years from now)

Drugs and Companies using MACITENTAN ingredient

Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription

136. Drug name - OPZELURA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598257	INCYTE CORP	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors	Dec, 2027 (5 years from now)
US8415362	INCYTE CORP	Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors	Dec, 2027 (5 years from now)
EP1966202B1	INCYTE CORP	Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors	Aug, 2027 (4 years from now)
EP1966202A1	INCYTE CORP	Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors	Aug, 2027 (4 years from now)

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
EQ 1.5% BASE	CREAM;TOPICAL	Prescription

137. Drug name - ORACEA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7749532	GALDERMA LABS LP	Once daily formulations of tetracyclines	Dec, 2027 (5 years from now)

Drugs and Companies using DOXYCYCLINE ingredient

Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
40MG	CAPSULE;ORAL	Prescription

138. Drug name - ORKAMBI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7495103	VERTEX PHARMS INC	Modulators of ATP-binding cassette transporters	May, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324242	VERTEX PHARMS INC	Modulators of ATP-binding cassette transporters	Aug, 2027 (4 years from now)

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor and ivacaftor

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
125MG/PACKET;100MG/PACKET	GRANULE;ORAL	Prescription
188MG/PACKET;150MG/PACKET	GRANULE;ORAL	Prescription

139. Drug name - OVIDE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7560445	TARO PHARM INDS LTD	Process for preparing malathion for pharmaceutical use	Feb, 2027 (4 years from now)

Drugs and Companies using MALATHION ingredient

Treatment: NA

Dosage: LOTION;TOPICAL

Strength	Dosage	Availability
0.5%	LOTION;TOPICAL	Discontinued

140. Drug name - OXTELLAR XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9351975	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (4 years from now)
US8821930	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (4 years from now)
US11166960	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (4 years from now)
US9855278	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (4 years from now)
US7910131	SUPERNUS PHARMS	Method of treating seizures using modified release formulations of oxcarbazepine	Apr, 2027 (4 years from now)
US9119791	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (4 years from now)
US9370525	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (4 years from now)
US10220042	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (4 years from now)
US8617600	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (4 years from now)
US7722898	SUPERNUS PHARMS	Modified-release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (4 years from now)

Drugs and Companies using OXCARBAZEPINE ingredient

Treatment: Treatment of partial-onset seizures

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
150MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
300MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
600MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

141. Drug name - OXYCONTIN

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8894988	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9763933	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9770416	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US8808741	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9492393	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9492391	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9492389	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9492392	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9775808	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
10MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
15MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
20MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
40MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
60MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
80MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

142. Drug name - OZEMPIC

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687611	NOVO	Injection device with torsion spring and rotatable display	Feb, 2027 (4 years from now)
US9457154	NOVO	Injection device with an end of dose feedback mechanism	Sep, 2027 (4 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/1.5ML (1.34MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription
4MG/3ML (1.34MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

143. Drug name - PENNSAID

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871809	HORIZON	Diclofenac topical formulation	Oct, 2027 (5 years from now)
US9168304	HORIZON	Diclofenac topical formulation	Oct, 2027 (5 years from now)
US9339551	HORIZON	Diclofenac topical formulation	Oct, 2027 (5 years from now)
US9066913	HORIZON	Diclofenac topical formulation	Oct, 2027 (5 years from now)
US9168305	HORIZON	Diclofenac topical formulation	Oct, 2027 (5 years from now)
US9132110	HORIZON	Treatment of pain with topical diclofenac	Oct, 2027 (5 years from now)
US9220784	HORIZON	Diclofenac topical formulation	Oct, 2027 (5 years from now)
US9339552	HORIZON	Diclofenac topical formulation	Oct, 2027 (5 years from now)
US9539335	HORIZON	Diclofenac topical formulation	Oct, 2027 (5 years from now)
US8563613	HORIZON	Diclofenac topical formulation	Oct, 2027 (5 years from now)
US9101591	HORIZON	Diclofenac topical formulation	Oct, 2027 (5 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Use of topical diclofenac sodium for treating pain; Use of topical diclofenac for treating pain

Dosage: SOLUTION;TOPICAL

Strength	Dosage	Availability
2%	SOLUTION;TOPICAL	Prescription

144. Drug name - PHOSLYRA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089528	FRESENIUS MEDCL	Liquid compositions of calcium acetate	Jul, 2027 (4 years from now)
US8592480	FRESENIUS MEDCL	Liquid compositions of calcium acetate	Jul, 2027 (4 years from now)

Drugs and Companies using CALCIUM ACETATE ingredient

Treatment: Use of phoslyra for reduction of serum phosphorous in patients

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
667MG/5ML	SOLUTION;ORAL	Prescription

145. Drug name - PICATO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8278292	LEO LABS	Therapeutic compositions	Jul, 2027 (4 years from now)

Drugs and Companies using INGENOL MEBUTATE ingredient

Treatment: NA

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
0.015%	GEL;TOPICAL	Discontinued
0.05%	GEL;TOPICAL	Discontinued

146. Drug name - PRADAXA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7866474	BOEHRINGER INGELHEIM	Film container	Aug, 2027 (4 years from now)

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 75MG BASE	CAPSULE;ORAL	Prescription
EQ 110MG BASE	CAPSULE;ORAL	Prescription
EQ 150MG BASE	CAPSULE;ORAL	Prescription

147. Drug name - PREZCOBIX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700645 (Pediatric)	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Jun, 2027 (4 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;800MG	TABLET;ORAL	Prescription

148. Drug name - PREZISTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700645 (Pediatric)	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Jun, 2027 (4 years from now)

Drugs and Companies using DARUNAVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
75MG	TABLET;ORAL	Prescription
150MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Discontinued
400MG	TABLET;ORAL	Discontinued
600MG	TABLET;ORAL	Prescription
800MG	TABLET;ORAL	Prescription

149. Drug name - PRISTIQ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8269040	PF PRISM CV	Derivatives of venlafaxine and methods of preparing and using the same	Jul, 2027 (4 years from now)

Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 25MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 50MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 100MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

150. Drug name - PROCYSBI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9925157	HORIZON	Enterically coated cysteamine, cystamine and derivatives thereof	Jan, 2027 (4 years from now)
US9925158	HORIZON	Enterically coated cysteamine, cystamine and derivatives thereof	Jan, 2027 (4 years from now)
US9925156	HORIZON	Enterically coated cysteamine, cystamine and derivatives thereof	Jan, 2027 (4 years from now)
EP2535044B1	HORIZON	Enterically Coated Cysteamine Bitartrate And Cystamine	Jan, 2027 (4 years from now)
EP2535044A1	HORIZON	Enterically Coated Cysteamine Bitartrate And Cystamine	Jan, 2027 (4 years from now)
EP1919458A4	HORIZON	Enterically Coated Cysteamine, Cystamine And Derivatives Thereof	Jan, 2027 (4 years from now)
EP1919458B3	HORIZON	Enterically Coated Cysteamine, Cystamine And Derivatives Thereof	Jan, 2027 (4 years from now)
EP1919458B1	HORIZON	Enterically Coated Cysteamine, Cystamine And Derivatives Thereof	Jan, 2027 (4 years from now)
EP1919458A2	HORIZON	Enterically Coated Cysteamine, Cystamine And Derivatives Thereof	Jan, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192590	HORIZON	Enterically coated cysteamine, cystamine and derivatives thereof	Jan, 2027 (4 years from now)
US9198882	HORIZON	Enterically coated cysteamine, cystamine and derivatives thereof	Jan, 2027 (4 years from now)
US9192590 (Pediatric)	HORIZON	Enterically coated cysteamine, cystamine and derivatives thereof	Jul, 2027 (4 years from now)
US9198882 (Pediatric)	HORIZON	Enterically coated cysteamine, cystamine and derivatives thereof	Jul, 2027 (4 years from now)
US8026284	HORIZON	Enterically coated cystamine, cysteamine and derivatives thereof	Sep, 2027 (4 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
EQ 25MG BASE	CAPSULE, DELAYED RELEASE;ORAL	Prescription
EQ 75MG BASE	CAPSULE, DELAYED RELEASE;ORAL	Prescription

151. Drug name - PROCYSBI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925157	HORIZON PHARMA USA	Enterically coated cysteamine, cystamine and derivatives thereof	Jan, 2027 (4 years from now)
US9925158	HORIZON PHARMA USA	Enterically coated cysteamine, cystamine and derivatives thereof	Jan, 2027 (4 years from now)
US9192590	HORIZON PHARMA USA	Enterically coated cysteamine, cystamine and derivatives thereof	Jan, 2027 (4 years from now)
US9198882	HORIZON PHARMA USA	Enterically coated cysteamine, cystamine and derivatives thereof	Jan, 2027 (4 years from now)
US9925156	HORIZON PHARMA USA	Enterically coated cysteamine, cystamine and derivatives thereof	Jan, 2027 (4 years from now)
US9198882 (Pediatric)	HORIZON PHARMA USA	Enterically coated cysteamine, cystamine and derivatives thereof	Jul, 2027 (4 years from now)
US9192590 (Pediatric)	HORIZON PHARMA USA	Enterically coated cysteamine, cystamine and derivatives thereof	Jul, 2027 (4 years from now)
US8026284	HORIZON PHARMA USA	Enterically coated cystamine, cysteamine and derivatives thereof	Sep, 2027 (4 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: GRANULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
EQ 75MG BASE/PACKET	GRANULE, DELAYED RELEASE;ORAL	Prescription
EQ 300MG BASE/PACKET	GRANULE, DELAYED RELEASE;ORAL	Prescription

152. Drug name - PROMACTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062665	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Aug, 2027 (4 years from now)
US8071129	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Aug, 2027 (4 years from now)
US8052994	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)

Pharsight

Drug Patents Expiring in 2027

1. Drug name - ABILIFY

2. Drug name - ABILIFY MYCITE KIT

3. Drug name - ABRAXANE

4. Drug name - ACTOPLUS MET

5. Drug name - ACULAR LS

6. Drug name - ADRENACLICK

7. Drug name - ADVIL ALLERGY SINUS

8. Drug name - ALSUMA

9. Drug name - ALTABAX

10. Drug name - AMITIZA

11. Drug name - AMYVID

12. Drug name - ANORO ELLIPTA

13. Drug name - ANTIZOL

14. Drug name - ARGATROBAN IN SODIUM CHLORIDE

15. Drug name - ARNUITY ELLIPTA

16. Drug name - AUBAGIO

17. Drug name - AUVI-Q

18. Drug name - AVEED

19. Drug name - AXIRON

20. Drug name - AZILECT

21. Drug name - BALCOLTRA

22. Drug name - BAXDELA

23. Drug name - BELBUCA

24. Drug name - BELEODAQ

25. Drug name - BREO ELLIPTA

26. Drug name - BUNAVAIL

27. Drug name - BYDUREON

28. Drug name - BYDUREON BCISE

29. Drug name - BYFAVO

30. Drug name - BYVALSON

31. Drug name - CAMCEVI KIT

32. Drug name - CARDENE

33. Drug name - CHLORAPREP ONE-STEP

34. Drug name - CHLORHEXIDINE GLUCONATE

35. Drug name - COLAZAL

36. Drug name - COMBIVENT RESPIMAT

37. Drug name - CONTRAVE

38. Drug name - CORLANOR

39. Drug name - CRESEMBA

40. Drug name - DAKLINZA

41. Drug name - DEXILANT

42. Drug name - DIFICID

43. Drug name - DOVATO

44. Drug name - DSUVIA

45. Drug name - DUAKLIR PRESSAIR

46. Drug name - DUAVEE

47. Drug name - DUETACT

48. Drug name - DURYSTA

49. Drug name - DYANAVEL XR

50. Drug name - DYANAVEL XR 10

51. Drug name - DYLOJECT

52. Drug name - EDLUAR

53. Drug name - ELEPSIA XR

54. Drug name - EMBEDA

55. Drug name - EMEND

56. Drug name - EMEND

57. Drug name - EMPAVELI

58. Drug name - ENTRESTO

59. Drug name - EPIDUO

60. Drug name - ERLEADA

61. Drug name - ESBRIET

62. Drug name - EUCRISA

63. Drug name - EVZIO

64. Drug name - EVZIO (AUTOINJECTOR)

65. Drug name - FANAPT

66. Drug name - FARXIGA

67. Drug name - FIBRICOR

68. Drug name - FINACEA

69. Drug name - FLOLIPID

70. Drug name - FORFIVO XL

71. Drug name - GALAFOLD

72. Drug name - GENOSYL

73. Drug name - GENVOYA

74. Drug name - GILENYA

75. Drug name - GILOTRIF

76. Drug name - GLYXAMBI

77. Drug name - HALAVEN

78. Drug name - HYSINGLA ER